Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib efficacy evaluation in metastatic colorectal cancer
ChiCTR2300073039Phase 4Recruiting
- Sponsor
- Maoming People's Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of regorafenib in colorectal cancer (CRC) (2 arms), sponsored by Maoming People's Hospital. Primary endpoints: Disease control rate, Partial response and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300073039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073039.